• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Delayed contrast MR may predict rheumatoid arthritis

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 32 No 11
Volume 32
Issue 11

Delayed gadolinium enhancement during MR imaging of cartilage of the metacarpophalangeal joints in patients with rheumatoid arthritis is feasible at 3T and may help predict rheumatoid arthritis.

Delayed gadolinium enhancement during MR imaging of cartilage of the metacarpophalangeal joints in patients with rheumatoid arthritis is feasible at 3T and may help predict rheumatoid arthritis.

The procedure involves T1 mapping following intravenous contrast. Concentration of the contrast in cartilage is an indirect measure of glycosaminoglycan (GAG), a component of hyaline cartilage.

The absence of GAG during delayed-contrast MR may help assess cartilage degeneration in the morphologically normal-appearing second and third metacarpophalangeal joints in patients.

Phalangeal and metacarpal delayed-enhancement values in patients with rheumatoid arthritis were significantly lower than in control subjects, although joint thickness was comparable in both groups, according to the researchers. Cartilage damage is a common occurrence in rheumatoid arthritis patients, so imaging may help for diagnosis and treatment purposes (Radiol 2010;257:441-447).

Recent Videos
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.